-

Tandem Diabetes Care to Announce First Quarter 2022 Financial Results on May 4, 2022

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2022 results after the financial markets close on Wednesday, May 4, 2022. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2022 financial and operating results.

Conference Call/Webcast Details:

Date: May 4, 2022
Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)
Toll Free Dial-In Number: (855) 427-4396
International Dial-In Number: (484) 756-4261
Conference ID: 2354706
Webcast Link: https://edge.media-server.com/mmc/p/i8hq38ud

An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The Company’s human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. For more information, visit tandemdiabetes.com.

Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2, and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.

Contacts

Media Contact:
Steve Sabicer
714-907-6264
ssabicer@thesabicergroup.com

Investor Contact:
Susan Morrison
858-366-6900
IR@tandemdiabetes.com

Tandem Diabetes Care, Inc.

NASDAQ:TNDM

Release Versions
$Cashtags

Contacts

Media Contact:
Steve Sabicer
714-907-6264
ssabicer@thesabicergroup.com

Investor Contact:
Susan Morrison
858-366-6900
IR@tandemdiabetes.com

Social Media Profiles
More News From Tandem Diabetes Care, Inc.

Tandem Diabetes Care Announces Appointment of Sandra Beaver to Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Sandra Beaver to its board of directors effective November 7, 2025. Ms. Beaver joins the board as an independent director and will serve on the board’s Audit Committee and Cybersecurity and Data Oversight Committee. “We welcome Sandra to our Board of Directors at this pivotal stage in Tandem’s evolution,” said John Sheridan, presid...

Tandem Mobi Receives FDA Clearance for Use with Android Smartphones

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Android version of the Tandem Mobi mobile app. Tandem Mobi, the world’s smallest, durable automated insulin delivery system 1, is powered by Control-IQ+ technology. Proven Control-IQ+ benefits include: Day 1 improvements2* 79% time in range3† 90% overnight time in range4* “We’re excited...

Tandem Diabetes Care Announces Third Quarter 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2025 and reaffirmed full year 2025 guidance. Third Quarter 2025 and Recent Highlights Achieved record third quarter sales both in the United States (U.S.) and internationally Demonstrated year-over-year and sequential gross margin improvement Progressed multi-channel initiative by: Increasing ph...
Back to Newsroom